Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Trial Profile

Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Docetaxel (Primary) ; Plinabulin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DUBLIN-3
  • Sponsors BeyondSpring Pharmaceuticals
  • Most Recent Events

    • 15 Jun 2017 According to BeyondSpring Pharmaceuticals media release, the company will present data from this study at the 2017 BIO International Conference.
    • 28 Apr 2017 According to BeyondSpring Pharmaceuticals media release, company expect to obtain interim data in the first quarter of 2018 and final data one year later during the first quarter of 2019.
    • 23 Feb 2017 According to BeyondSpring Pharmaceuticals media release, the company has announced that currently over 40 patients have been enrolled, and projects to have all 550 patients enrolled by early 2018, when interim data analysis will happen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top